Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980969808> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W2980969808 abstract "Fully automated Elecsys cerebrospinal fluid (CSF) immunoassays have been developed for amyloid and tau biomarkers, including for the P-tau/Aβ1-42 ratio. It is unknown how these novel amyloid and tau measures correlate with Alzheimer's disease (AD) neuropathology. CSF and neuropathology measures were compared in 101 patients, recruited at UCSF (clinical diagnoses were N=15 AD dementia, N=21 corticobasal syndrome/degeneration, N=14 progressive supranuclear palsy [PSP], N=26 behavioral variant frontotemporal lobe dementia [bvFTD], and N=25 others). CSF biomarkers were analyzed at Lund University and included Elecsys Aβ1–40, Aβ1–42, T-tau, P-tau. Neuropathology measures included Thal phases, Braak stages, CERAD scores, and Alzheimer's disease neuropathologic change (ADNC). CSF samples were collected a mean of 2.9 years prior to death (range 0.2−7.5 years). In 45 patients, amyloid PET imaging had been done using 11C-PiB or 18F-Florbetapir (using visual read), a mean of 0.13 years prior to CSF sampling (range −3.3 to 1.8 years after). Associations were tested in regression models adjusted for age, sex, time from sampling to death, and clinical diagnosis. We tested continuous biomarkers and cut-points defined both a priori in a previous study (Hansson et al, Alzheimer's & Dementia, 2018), and by mixture modeling in a larger dataset of 575 UCSF subjects. The primary hypothesis was that higher P-tau/Aβ1-42 would correlate with more advanced AD neuropathology. High P-tau/Aβ1-42 was significantly associated with more advanced amyloid and tau pathology (Figure). A previously defined cut-point for CSF P-tau/Aβ1-42 (0.022), had high specificity (rarely positive in subjects with lack of pathology, e.g. 1/19 Thal phase 0, 2/52 CERAD “None”; 1/10 Braak stage 0, 1/19 ADNC “Not”), and high sensitivity (often positive in advanced neuropathology, 22/25 Thal phase 4-5, 25/28 CERAD “Frequent”, 19/20 Braak stage V-VI, 24/27 ADNC “Intermediate”-“High”). In the subset with amyloid PET, a few cases with transitional pathology (e.g. Thal phases 2-3, Braak stage II, ADNC “Low”) had elevated P-tau/Aβ1-42 despite negative amyloid PET (using visual read, Figure). The associations were similar for Aβ1-42/Aβ1-40, but less pronounced for individual biomarkers." @default.
- W2980969808 created "2019-10-25" @default.
- W2980969808 creator A5003878251 @default.
- W2980969808 creator A5007951256 @default.
- W2980969808 creator A5016730229 @default.
- W2980969808 creator A5019555711 @default.
- W2980969808 creator A5025008902 @default.
- W2980969808 creator A5045343267 @default.
- W2980969808 creator A5046120768 @default.
- W2980969808 creator A5046772800 @default.
- W2980969808 creator A5052536571 @default.
- W2980969808 creator A5066503440 @default.
- W2980969808 creator A5072009949 @default.
- W2980969808 creator A5074477451 @default.
- W2980969808 creator A5074694043 @default.
- W2980969808 creator A5077533143 @default.
- W2980969808 creator A5083219599 @default.
- W2980969808 creator A5087482235 @default.
- W2980969808 date "2019-07-01" @default.
- W2980969808 modified "2023-09-28" @default.
- W2980969808 title "P4-536: CEREBROSPINAL FLUID BIOMARKERS FOR AMYLOID AND TAU USING FULLY AUTOMATED ASSAYS: ASSOCIATIONS WITH NEUROPATHOLOGY" @default.
- W2980969808 doi "https://doi.org/10.1016/j.jalz.2019.08.083" @default.
- W2980969808 hasPublicationYear "2019" @default.
- W2980969808 type Work @default.
- W2980969808 sameAs 2980969808 @default.
- W2980969808 citedByCount "0" @default.
- W2980969808 crossrefType "journal-article" @default.
- W2980969808 hasAuthorship W2980969808A5003878251 @default.
- W2980969808 hasAuthorship W2980969808A5007951256 @default.
- W2980969808 hasAuthorship W2980969808A5016730229 @default.
- W2980969808 hasAuthorship W2980969808A5019555711 @default.
- W2980969808 hasAuthorship W2980969808A5025008902 @default.
- W2980969808 hasAuthorship W2980969808A5045343267 @default.
- W2980969808 hasAuthorship W2980969808A5046120768 @default.
- W2980969808 hasAuthorship W2980969808A5046772800 @default.
- W2980969808 hasAuthorship W2980969808A5052536571 @default.
- W2980969808 hasAuthorship W2980969808A5066503440 @default.
- W2980969808 hasAuthorship W2980969808A5072009949 @default.
- W2980969808 hasAuthorship W2980969808A5074477451 @default.
- W2980969808 hasAuthorship W2980969808A5074694043 @default.
- W2980969808 hasAuthorship W2980969808A5077533143 @default.
- W2980969808 hasAuthorship W2980969808A5083219599 @default.
- W2980969808 hasAuthorship W2980969808A5087482235 @default.
- W2980969808 hasBestOaLocation W29809698081 @default.
- W2980969808 hasConcept C118552586 @default.
- W2980969808 hasConcept C126322002 @default.
- W2980969808 hasConcept C142724271 @default.
- W2980969808 hasConcept C143998085 @default.
- W2980969808 hasConcept C15744967 @default.
- W2980969808 hasConcept C2776477761 @default.
- W2980969808 hasConcept C2776936178 @default.
- W2980969808 hasConcept C2778186239 @default.
- W2980969808 hasConcept C2778641062 @default.
- W2980969808 hasConcept C2779134260 @default.
- W2980969808 hasConcept C2779483572 @default.
- W2980969808 hasConcept C2779651940 @default.
- W2980969808 hasConcept C2780130745 @default.
- W2980969808 hasConcept C2781099131 @default.
- W2980969808 hasConcept C502032728 @default.
- W2980969808 hasConcept C71924100 @default.
- W2980969808 hasConceptScore W2980969808C118552586 @default.
- W2980969808 hasConceptScore W2980969808C126322002 @default.
- W2980969808 hasConceptScore W2980969808C142724271 @default.
- W2980969808 hasConceptScore W2980969808C143998085 @default.
- W2980969808 hasConceptScore W2980969808C15744967 @default.
- W2980969808 hasConceptScore W2980969808C2776477761 @default.
- W2980969808 hasConceptScore W2980969808C2776936178 @default.
- W2980969808 hasConceptScore W2980969808C2778186239 @default.
- W2980969808 hasConceptScore W2980969808C2778641062 @default.
- W2980969808 hasConceptScore W2980969808C2779134260 @default.
- W2980969808 hasConceptScore W2980969808C2779483572 @default.
- W2980969808 hasConceptScore W2980969808C2779651940 @default.
- W2980969808 hasConceptScore W2980969808C2780130745 @default.
- W2980969808 hasConceptScore W2980969808C2781099131 @default.
- W2980969808 hasConceptScore W2980969808C502032728 @default.
- W2980969808 hasConceptScore W2980969808C71924100 @default.
- W2980969808 hasIssue "7S_Part_29" @default.
- W2980969808 hasLocation W29809698081 @default.
- W2980969808 hasOpenAccess W2980969808 @default.
- W2980969808 hasPrimaryLocation W29809698081 @default.
- W2980969808 hasRelatedWork W136053174 @default.
- W2980969808 hasRelatedWork W1546901506 @default.
- W2980969808 hasRelatedWork W1973863166 @default.
- W2980969808 hasRelatedWork W1978318495 @default.
- W2980969808 hasRelatedWork W2094261122 @default.
- W2980969808 hasRelatedWork W2503795360 @default.
- W2980969808 hasRelatedWork W2980953456 @default.
- W2980969808 hasRelatedWork W3095639822 @default.
- W2980969808 hasRelatedWork W3200820683 @default.
- W2980969808 hasRelatedWork W4353018166 @default.
- W2980969808 hasVolume "15" @default.
- W2980969808 isParatext "false" @default.
- W2980969808 isRetracted "false" @default.
- W2980969808 magId "2980969808" @default.
- W2980969808 workType "article" @default.